KarXT

FDA kicks off review of Karuna’s schizophrenia drug KarXT
FDA kicks off review of Karuna’s schizophrenia drug KarXT
Pharmaphorum
Karuna
KarXT
FDA
schizophrenia
Flag link:
Karuna keeps $6B sales forecast alive with blood pressure data on schizophrenia drug
Karuna keeps $6B sales forecast alive with blood pressure data on schizophrenia drug
Fierce Biotech
Karuna Therapeutics
KarXT
blood pressure
schizophrenia
Flag link:
Karuna submits schizophrenia drug for US approval
Karuna submits schizophrenia drug for US approval
BioPharma Dive
Karuna Therapeutics
KarXT
schizophrenia
FDA
Flag link:
The 10 highest value R&D projects in biopharma
The 10 highest value R&D projects in biopharma
Fierce Biotech
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
Flag link:
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Flag link:
Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful
Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful
Endpoints
Royalty Pharma
Karuna Therapeutics
KarXT
schizophrenia
PureTech
Flag link:
Karuna’s schizophrenia drug succeeds in a second late-stage trial
Karuna’s schizophrenia drug succeeds in a second late-stage trial
BioPharma Dive
Karuna
clinical trials
schizophrenia
KarXT
Flag link:
JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate
JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate
Fierce Biotech
JPMHC 2023
Karuna Therapeutics
drug launches
schizophrenia
KarXT
Flag link:
Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch
Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch
Fierce Biotech
Karuna Therapeutics
schizophrenia
KarXT
drug launches
Flag link:
Karuna switches CEOs ahead of FDA filing for schizophrenia drug
Karuna switches CEOs ahead of FDA filing for schizophrenia drug
BioPharma Dive
Karuna Therapeutics
Pharma CEOs
schizophrenia
FDA
KarXT
Flag link:
Karuna’s resurrection of Lilly drug delivers phase 3 schizophrenia success, teeing up 2023 filing
Karuna’s resurrection of Lilly drug delivers phase 3 schizophrenia success, teeing up 2023 filing
Fierce Biotech
Karuna Therapeutics
clinical trials
schizophrenia
KarXT
Flag link:
Karuna seeks a novel schizophrenia mechanism
Karuna seeks a novel schizophrenia mechanism
EP Vantage
Karuna Therapeutics
antipsychotics
schizophrenia
KarXT
Flag link:
10 clinical trials to watch in the first half of 2022
10 clinical trials to watch in the first half of 2022
BioPharma Dive
clinical trials
Pfizer
Arena Pharmaceuticals
etrasimod
Sanofi
GSK
vaccines
COVID-19
Roche
gantenerumab
AbbVie
Gilead Sciences
Trodelvy
Karuna Therapeutics
KarXT
Intercept Pharma
obeticholic acid
Allogene
ALLO-501a
Flag link:
Karuna's 'A-ha moment': A billion-dollar stock swing and new expectations
Karuna's 'A-ha moment': A billion-dollar stock swing and new expectations
Biopharma Dive
Karuna
schizophrenia
KarXT
Flag link:
Karuna Therapeutics Files for $52 Million Offering
Karuna Therapeutics Files for $52 Million Offering
CP Wire
Karuna Therapeutics
schizophrenia
KarXT
Flag link:
Karuna Therapeutics Files for $52 Million Offering
Karuna Therapeutics
schizophrenia
psychosis
KarXT
Flag link:
Karuna Therapeutics Shares Rip Higher After Schizophrenia Drug Aces Midstage Trial
Karuna Therapeutics Shares Rip Higher After Schizophrenia Drug Aces Midstage Trial
Benzinga
Karuna Therapeutics
schizophrenia
clinical trials
KarXT
Flag link:
Karuna looks past schizophrenia with $68M series B
Karuna looks past schizophrenia with $68M series B
BioCentury
Karuna
KarXT
schizophrenia
geriatric psychosis
pain
Flag link:
Karuna raises $42M to resurrect abandoned Lilly drug for schizophrenia
Karuna raises $42M to resurrect abandoned Lilly drug for schizophrenia
Fierce Biotech
Karuna Pharmaceuticals
Eli Lilly
schizophrenia
Alzheimer's disease
KarXT
xanomeline
Flag link: